| HOME >> BIOLOGY >> TECHNOLOGY |
Three months ended
March 31,
2008 2007
Expenses
Research and development, gross $2,778,234 $2,906,739
Grants - (336,641)
Research and development, net of grants 2,778,234 2,570,098
General and administrative 796,924 2,460,696
Depreciation and amortization 34,552 69,568
Total operating expenses 3,609,710 5,100,362
Loss from operations (3,609,710) (5,100,362)
Other (expense) income
Interest income 130,700 330,158
Interest expense (122,862) -
Other income 6,989 17,109
Other income, net 14,827 347,267
Net loss ($3,594,883) ($4,753,095)
Net loss per share
- basic and diluted ($0.14) ($0.19)
Weighted average shares outstanding
- basic and diluted 25,739,855 25,563,367
Select Consolidated Balance Sheet Data
March 31, 2008 December 31, 2007
Cash and short-term investments $11,327,248 $11,168,309
Working capital $10,031,767 $9,504,348
Shareholder's equity $6,549,530 $9,984,665
| SOURCE Pharmos Corporation Copyright©2008 PR Newswire. All rights reserved |